Errata

Erratum to: Management of transthyretin amyloidosis

Erratum to Swiss Med Wkly. 2021;151:w30053 (DOI 10.4414/smw.2021.w30053)

DOI: https://doi.org/10.4414/smw.2021.w30104
Publication Date: 04.11.2021
Swiss Med Wkly. 2021;151:w30104

Please find the affiliations for this article in the PDF.

The published manuscript contained a typing error in the chapter ‘Wild-type transthyretin amyloidosis (ATTRwt)’, subchapter ‘Treatment’ (page 13 of the PDF version). It reads: Treatment with tafamidis 61 mg should be considered for patients with cardiac ATTRwt amyloidosis and dyspnea NYHA I-II. [IIa, B].

The correct wording is: Treatment with tafamidis 61 mg should be considered for patients with cardiac ATTRwt amyloidosis and dyspnea NYHA I-III. [IIa, B].

The error occured during manuscript editing and is not in the authors responsability. It has now been corrected online. We apologize to the authors and readers for this error.

Verpassen Sie keinen Artikel!

close